多瑞医药
(301075)
| 流通市值：24.32亿 | | | 总市值：24.32亿 |
| 流通股本：8000.00万 | | | 总股本：8000.00万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 200,520,158.82 | 150,380,490.51 | 78,457,398.26 | 334,299,367.07 |
| 营业收入 | 200,520,158.82 | 150,380,490.51 | 78,457,398.26 | 334,299,367.07 |
| 二、营业总成本 | 233,238,610.81 | 162,260,202.56 | 84,406,149.31 | 330,581,938.82 |
| 营业成本 | 118,802,890.86 | 91,836,317.76 | 47,485,816.29 | 105,129,895.45 |
| 税金及附加 | 1,427,645.97 | 1,051,236.71 | 397,392.35 | 3,873,836.77 |
| 销售费用 | 63,176,797.95 | 42,980,480.94 | 22,638,749.57 | 161,846,041.25 |
| 管理费用 | 31,152,149.87 | 19,778,014.62 | 10,715,882.74 | 40,284,049.35 |
| 研发费用 | 17,986,703.87 | 6,413,461.72 | 3,017,966.19 | 23,995,269.4 |
| 财务费用 | 692,422.29 | 200,690.81 | 150,342.17 | -4,547,153.4 |
| 其中:利息费用 | 4,272,293.15 | 2,766,501.51 | 1,412,640.46 | 3,112,531.97 |
| 其中:利息收入 | 3,678,758.22 | 2,650,942.4 | 1,275,825.3 | 7,715,282.39 |
| 加:公允价值变动收益 | 531,891.89 | 251,984.94 | - | 66,000 |
| 加:投资收益 | 6,153,254.01 | 3,929,896.88 | 2,467,690.07 | 5,643,510.4 |
| 资产处置收益 | 22,631.75 | -22,651.26 | - | 82,888.78 |
| 资产减值损失(新) | 455,047.8 | 499,141.88 | -2,451.55 | -1,061,824.27 |
| 信用减值损失(新) | -405,561.8 | 257,982.45 | -81,557.24 | 964,627.19 |
| 其他收益 | 231,056.25 | 109,396.68 | 62,078.72 | 12,774,547.19 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -25,730,132.09 | -6,853,960.48 | -3,502,991.05 | 22,187,177.54 |
| 加:营业外收入 | 51,155.77 | 322,162.34 | 1,767.29 | 625,745.69 |
| 减:营业外支出 | 503,844.43 | 107,399.44 | 3,964.5 | 564,094.59 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -26,182,820.75 | -6,639,197.58 | -3,505,188.26 | 22,248,828.64 |
| 减:所得税费用 | 375,516.07 | 1,155,436.26 | 69,759.28 | 5,157,106.54 |
| 六、净利润 | -26,558,336.82 | -7,794,633.84 | -3,574,947.54 | 17,091,722.1 |
| 持续经营净利润 | -26,558,336.82 | -7,794,633.84 | -3,574,947.54 | 17,091,722.1 |
| 归属于母公司股东的净利润 | -17,078,738.2 | -3,276,411.4 | -2,537,276.14 | 18,850,748.34 |
| 少数股东损益 | -9,479,598.62 | -4,518,222.44 | -1,037,671.4 | -1,759,026.24 |
| (一)基本每股收益 | -0.21 | -0.04 | -0.03 | 0.24 |
| (二)稀释每股收益 | -0.21 | -0.04 | -0.03 | 0.24 |
| 八、其他综合收益 | - | - | - | 1,971,922.32 |
| 归属于母公司股东的其他综合收益 | - | - | - | 1,971,922.32 |
| 九、综合收益总额 | -26,558,336.82 | -7,794,633.84 | -3,574,947.54 | 19,063,644.42 |
| 归属于母公司股东的综合收益总额 | -17,078,738.2 | -3,276,411.4 | -2,537,276.14 | 20,822,670.66 |
| 归属于少数股东的综合收益总额 | -9,479,598.62 | -4,518,222.44 | -1,037,671.4 | -1,759,026.24 |
| 公告日期 | 2024-10-25 | 2024-08-27 | 2024-04-25 | 2024-04-18 |
| 审计意见(境内) | | | | 标准无保留意见 |